Journal of Yeungnam Medical Science

Original article

Performance evaluation of Barozen Lipid Plus for point-of-care testing of lipid profiles: a method comparison study: Soojoung Yu, Hwa Yeon Sun, Byungwook Yoo; J Yeungnam Med Sci. 2023;40(Suppl):S73-S80. Published online October 20, 2023; DOI: https://doi.org/10.12701/jyms.2023.00528

771 View
29 Download

Abstract PDF Supplementary Material: Background
The quick and easy nature of point-of-care (POC) testing devices allows regular monitoring of serum lipid levels to increase efficiency. The purpose of this study was to assess a POC lipid analyzer, Barozen Lipid Plus (MICO Biomed Co., Ltd.), which uses capillary blood to measure total cholesterol (TC), triglycerides (TGs), and high-density lipoprotein cholesterol (HDL-C).
Methods
Capillary and venous blood samples were collected from 110 participants at a single center in Korea between June 10 and June 26, 2021. TC, TG, and HDL-C measurements using Barozen Lipid Plus were compared with measurements using our reference device, the Roche-Hitachi Cobas 8000 c702 (Hitachi High-Technologies Corporation). This study followed the guidelines of the Clinical and Laboratory Standards Institute and the Clinical Laboratory Improvement Amendments. We surveyed participants regarding the convenience of the POC device using a questionnaire following the completion of blood collection.
Results
When compared to the reference equipment, the measurements obtained using Barozen Lipid Plus were more than 95% satisfactory within TC±10%, TG±25%, and HDL-C±30%. The coefficient of variation in the repeatability testing was within 5% for TC, 5% for TGs, and 7% for HDL-C. The survey results indicated high levels of satisfaction. No adverse events were reported.
Conclusion
These findings suggest that Barozen Lipid Plus is reliable for measuring lipid profiles and can therefore be used to monitor lipid levels at the time and place of patient care.

Original Article

The effect of thalidomide on visceral fat pad mass and triglyceride concentration of the skeletal muscles in rats: Ki-Hoon Kim, Chang-Bon Choi, Jong-Yeon Kim; Yeungnam Univ J Med. 2018;35(2):213-218. Published online December 31, 2018; DOI: https://doi.org/10.12701/yujm.2018.35.2.213

5,329 View
52 Download
1 Crossref

Background
Body fats, especially both of abdominal fat pad mass and skeletal muscle fat content, are inversely related to insulin action. Therefore, methods for decreasing visceral fat mass and muscle triglyceride content may be helpful for the prevention of insulin resistance.
Methods
Thalidomide, used for its anti-angiogenic and anti-inflammatory properties, was administered to rats for 4 weeks. A 10% solution of thalidomide in dimethyl sulfoxide was injected daily into the peritoneal cavity as much as 100 mg/kg of body weight.
Results
The total visceral fat pad mass in the thalidomide-treated group was 11% lower than in the control group. The size of adipocytes of the epididymal fat pad mass in the thalidomide-treated group was smaller than in the control group. The intraperitoneal thalidomide treatment increased triglyceride concentrations by 16% in the red muscle, but not in the white muscle.
Conclusion
The results suggested that intraperitoneal thalidomide treatment inhibited abdominal fat accumulation, and that the free fatty acids in the blood were preferentially accumulated in the red muscle rather than in the white muscle.

Citations

Citations to this article as recorded by

Thalidomide suppresses migration and invasion of colorectal cancer cells by inhibiting HOXB7‐mediated activation of the Wnt/β‐catenin signaling pathway
Liyang Liu, Wusong Xue
Chemical Biology & Drug Design.2024;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search